Get to know our clinical trials
Phase 2/3 study of (Neo)adjuvant V940 and pembrolizumab in cSCC
THE MAIN OBJECTIVE IS TO COMPARE V940 PLUS PEMBROLIZUMAB WITH SOC WITH RESPECT TO EFS.
Technical Summary
- PHASE 2/3, ADAPTIVE, RANDOMIZED, OPEN-LABEL CLINICAL TRIAL TO EVALUATE NEOADJUVANT AND ADJUVANT V940 (MRNA-4157) IN COMBINATION WITH PEMBROLIZUMAB (MK-3475) VS. TREATMENT AS USUAL AND PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH RESECTABLE LOCALLY ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA (LA SCC) (INTERPATH-007).
- Code EudraCT: 2023-505712-37
- Protocol number: V940-007
- Promoter: Merck Sharp & Dohme, S.A.
- Molecule/Drug: V940
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.